Safety,Tolerability and Pharmacokinetics of Orally Inhaled Zanamivir: A Randomized Study Comparing Rotacap/Rotahaler and Rotadisk/Diskhaler in Healthy Adults
Free accessAnnouncementFirst published online August, 2013
Safety,Tolerability and Pharmacokinetics of Orally Inhaled Zanamivir: A Randomized Study Comparing Rotacap/Rotahaler and Rotadisk/Diskhaler in Healthy Adults
During a pandemic, the need for available anti-influenza medications increases. There has been extensive use of the approved zanamivir Rotadisk/Diskhaler but no clinical data are available for administration by an alternative Rotacap/Rotahaler presentation.
Methods
In this randomized three-way crossover study, each healthy adult received zanamivir 10 mg every 12 h for 5 days via Rotadisk/Diskhaler, via Rotacap/Rotahaler and placebo via Rotacap/Rotahaler, with a washout period between treatments. Safety assessments were conducted throughout the study and at follow-up. Serial blood samples for pharmacokinetic analysis were collected over a 12-h dose interval on day 5 of each treatment period. Pharmacokinetic parameters were compared using a mixed-effects model.
Results
A total of 18 healthy adults were recruited and 17 subjects completed the study. A total of 20 adverse events (AEs) were reported (all grade 1) by nine subjects, with no AE reported ≥1x in any treatment group. Nasal congestion, reported by one subject in the zanamivir Rotadisk/Diskhaler group, was the only drug-related AE. No serious AEs or withdrawals due to AEs occurred during the study. There were no significant changes in clinical laboratory values, vital signs or spirometry. Serum zanamivir exposures were similar after administration via Rotacap/Rotahaler and Rotadisk/Diskhaler. Both oral inhalation presentations are likely to deliver similar zanamivir concentrations to sites of influenza infection in the respiratory tract.
Conclusions
The safety and pharmacokinetic results from this study support the use of the Rotacap/Rotahaler presentation, potentially allowing an increased number of zanamivir treatment courses to be supplied in the event of an influenza pandemic.
CassL.M.R., EfthymiopoulosC., ByeA.Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet1999; 36Suppl 1: 1–11.
6.
SheltonM.J., LovernM., Ng-CashinJ.Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects. Antimicrob Agents Chemother2011; 55: 5178–5184.
7.
PengA.W., MilleriS., SteinD.S.Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation. Antimicrob Agents Chemother2000; 44: 1974–1976.
8.
Daley-YatesP.T., ParkinsD.A.Establishing bioequivalence for inhaled drugs; weighing the evidence. Expert Opin Drug Deliv2011; 8: 1297–1308.
